Author

Cameron Holberg

University of Arizona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Andrew L. PaekiD· 1 shared Briana A. Guzman· 1 shared Carly R. CabeliD· 1 shared Chonlarat WichaiditiD· 1 shared Curtis A. ThorneiD· 1 shared Darren A. CusanovichiD· 1 shared Elaheh AlizadehiD· 1 shared Gregory R. J. ThatcheriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Andrew L. PaekORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors.

Carly R. Cabel, Briana A. Guzman, Elaheh Alizadeh, Shuaizhi Li, Cameron Holberg, Chonlarat Wichaidit, Darren A. Cusanovich, Andrew L. Paek, Gregory R. J. Thatcher, Koenraad Van Doorslaer, Rachel S. Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, James E. Crowe, Robert H. Carnahan, , Curtis A. Thorne

This study uses high-throughput screens in human cells with authentic SARS-CoV-2 virus to identify neutralizing monoclonal antibodies and kinase inhibitors with minimal host toxicity.

Frontiers in Cell and Developmental Biology · May 22, 2025Peer-reviewedPharmacology & Toxicology